In vitro platforms for evaluating liver toxicity

Shyam Sundhar Bale, Lawrence Vernetti, Nina Senutovitch, Rohit Jindal, Manjunath Hegde, Albert Gough, William J. McCarty, Ahmet Bakan, Abhinav Bhushan, Tong Y. Shun, Inna Golberg, Richard DeBiasio, O. Berk Usta, D. Lansing Taylor, Martin L. Yarmush

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.

Original languageEnglish (US)
Pages (from-to)1180-1191
Number of pages12
JournalExperimental Biology and Medicine
Volume239
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Liver
Toxicity
Pharmaceutical Preparations
Metabolism
Hepatocytes
Wounds and Injuries
Animal Models
Animals
Chemical and Drug Induced Liver Injury
Microfluidics
In Vitro Techniques
Biosensing Techniques
Cellular Structures
Endothelial cells
Cell Communication
Metabolites
Nanotechnology
Biosensors
Macros
Endothelial Cells

Keywords

  • Drug-induced liver injury
  • hepatotoxicity
  • high content screening
  • liver on chip
  • predictive modeling

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Bale, S. S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., ... Yarmush, M. L. (2014). In vitro platforms for evaluating liver toxicity. Experimental Biology and Medicine, 239(9), 1180-1191. https://doi.org/10.1177/1535370214531872

In vitro platforms for evaluating liver toxicity. / Bale, Shyam Sundhar; Vernetti, Lawrence; Senutovitch, Nina; Jindal, Rohit; Hegde, Manjunath; Gough, Albert; McCarty, William J.; Bakan, Ahmet; Bhushan, Abhinav; Shun, Tong Y.; Golberg, Inna; DeBiasio, Richard; Usta, O. Berk; Taylor, D. Lansing; Yarmush, Martin L.

In: Experimental Biology and Medicine, Vol. 239, No. 9, 01.09.2014, p. 1180-1191.

Research output: Contribution to journalArticle

Bale, SS, Vernetti, L, Senutovitch, N, Jindal, R, Hegde, M, Gough, A, McCarty, WJ, Bakan, A, Bhushan, A, Shun, TY, Golberg, I, DeBiasio, R, Usta, OB, Taylor, DL & Yarmush, ML 2014, 'In vitro platforms for evaluating liver toxicity', Experimental Biology and Medicine, vol. 239, no. 9, pp. 1180-1191. https://doi.org/10.1177/1535370214531872
Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A et al. In vitro platforms for evaluating liver toxicity. Experimental Biology and Medicine. 2014 Sep 1;239(9):1180-1191. https://doi.org/10.1177/1535370214531872
Bale, Shyam Sundhar ; Vernetti, Lawrence ; Senutovitch, Nina ; Jindal, Rohit ; Hegde, Manjunath ; Gough, Albert ; McCarty, William J. ; Bakan, Ahmet ; Bhushan, Abhinav ; Shun, Tong Y. ; Golberg, Inna ; DeBiasio, Richard ; Usta, O. Berk ; Taylor, D. Lansing ; Yarmush, Martin L. / In vitro platforms for evaluating liver toxicity. In: Experimental Biology and Medicine. 2014 ; Vol. 239, No. 9. pp. 1180-1191.
@article{bd9df1664e5646278c64d408e38644a7,
title = "In vitro platforms for evaluating liver toxicity",
abstract = "The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.",
keywords = "Drug-induced liver injury, hepatotoxicity, high content screening, liver on chip, predictive modeling",
author = "Bale, {Shyam Sundhar} and Lawrence Vernetti and Nina Senutovitch and Rohit Jindal and Manjunath Hegde and Albert Gough and McCarty, {William J.} and Ahmet Bakan and Abhinav Bhushan and Shun, {Tong Y.} and Inna Golberg and Richard DeBiasio and Usta, {O. Berk} and Taylor, {D. Lansing} and Yarmush, {Martin L.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1177/1535370214531872",
language = "English (US)",
volume = "239",
pages = "1180--1191",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "9",

}

TY - JOUR

T1 - In vitro platforms for evaluating liver toxicity

AU - Bale, Shyam Sundhar

AU - Vernetti, Lawrence

AU - Senutovitch, Nina

AU - Jindal, Rohit

AU - Hegde, Manjunath

AU - Gough, Albert

AU - McCarty, William J.

AU - Bakan, Ahmet

AU - Bhushan, Abhinav

AU - Shun, Tong Y.

AU - Golberg, Inna

AU - DeBiasio, Richard

AU - Usta, O. Berk

AU - Taylor, D. Lansing

AU - Yarmush, Martin L.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.

AB - The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.

KW - Drug-induced liver injury

KW - hepatotoxicity

KW - high content screening

KW - liver on chip

KW - predictive modeling

UR - http://www.scopus.com/inward/record.url?scp=84907016464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907016464&partnerID=8YFLogxK

U2 - 10.1177/1535370214531872

DO - 10.1177/1535370214531872

M3 - Article

C2 - 24764241

AN - SCOPUS:84907016464

VL - 239

SP - 1180

EP - 1191

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 9

ER -